Areima^®

International nonproprietary name

Camrelizumab

Description

A monoclonal anti-PD-1 antibody, that reactivates tumor-specific cytotoxic T lymphocytes, and stimulates the anti-tumor immune response for the therapy of cancer.

Application

• Treatment of locally advanced or metastatic esophageal squamous cell carcinoma in combination with paclitaxel and cisplatin as 1st line therapy.
• As monotherapy for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma with disease progression after previous chemotherapy or intolerance to 1st line of therapy.
• Treatment for recurrent or metastatic nasopharyngeal carcinoma in combination with gemcitabine and cisplatin as 1st line therapy.
• First-line treatment of locally advanced or metastatic non-squamous NSCLC without EGFR or ALK mutations in combination with pemetrexed and carboplatin.
• First-line treatment of locally advanced or metastatic squamous NSCLC in combination with paclitaxel and carboplatin.